Press release
PHAXIAM Receives Compliance Notice from Nasdaq
PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM today announced that it has received confirmation
from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2).